197 related articles for article (PubMed ID: 35017148)
21. Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model.
Lisiero DN; Soto H; Liau LM; Prins RM
J Immunol; 2011 May; 186(9):5068-77. PubMed ID: 21430221
[TBL] [Abstract][Full Text] [Related]
22. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8
Dwyer CJ; Arhontoulis DC; Rangel Rivera GO; Knochelmann HM; Smith AS; Wyatt MM; Rubinstein MP; Atkinson C; Thaxton JE; Neskey DM; Paulos CM
Eur J Immunol; 2020 Sep; 50(9):1386-1399. PubMed ID: 32383488
[TBL] [Abstract][Full Text] [Related]
23. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
24. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
25. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8
Rolig AS; Rose DC; McGee GH; Rubas W; Kivimäe S; Redmond WL
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35444059
[TBL] [Abstract][Full Text] [Related]
26. Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice.
Montinaro A; Forte G; Sorrentino R; Luciano A; Palma G; Arra C; Adcock IM; Pinto A; Morello S
PLoS One; 2012; 7(9):e45401. PubMed ID: 23028986
[TBL] [Abstract][Full Text] [Related]
27. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
28. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
29. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
30. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
31. IL7-Fc Enhances the Efficacy of Adoptive T Cell Therapy under Lymphopenic Conditions in a Murine Melanoma Model.
Yu EM; Cho E; Singh R; Kim SH; Han C; Han S; Lee DG; Kim YH; Kwon BS; Choi BK
Cells; 2021 Aug; 10(8):. PubMed ID: 34440787
[TBL] [Abstract][Full Text] [Related]
32. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.
Shi LZ; Goswami S; Fu T; Guan B; Chen J; Xiong L; Zhang J; Ng Tang D; Zhang X; Vence L; Blando J; Allison JP; Collazo R; Gao J; Sharma P
Cancer Immunol Res; 2019 Nov; 7(11):1803-1812. PubMed ID: 31466995
[TBL] [Abstract][Full Text] [Related]
33. Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L.
Díaz-Montero CM; Zidan AA; Pallin MF; Anagnostopoulos V; Salem ML; Wieder E; Komanduri K; Montero AJ; Lichtenheld MG
Immunol Res; 2013 Dec; 57(1-3):23-33. PubMed ID: 24218360
[TBL] [Abstract][Full Text] [Related]
34. BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control.
McGray AJR; Chiello JL; Tsuji T; Long M; Maraszek K; Gaulin N; Rosario SR; Hess SM; Abrams SI; Kozbor D; Odunsi K; Zsiros E
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37647218
[TBL] [Abstract][Full Text] [Related]
35. Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8+ T cells in Breast Cancer Implications for Adoptive Cell Therapy.
Gattas GI; Noël G; López F; González F; Prieto-Hinojosa A; Nava-Rivera LE; Willard-Gallo K; Argüello JR
Curr Pharm Biotechnol; 2023 Sep; ():. PubMed ID: 37680154
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.
Rubinstein MP; Su EW; Suriano S; Cloud CA; Andrijauskaite K; Kesarwani P; Schwartz KM; Williams KM; Johnson CB; Li M; Scurti GM; Salem ML; Paulos CM; Garrett-Mayer E; Mehrotra S; Cole DJ
Cancer Immunol Immunother; 2015 May; 64(5):539-49. PubMed ID: 25676709
[TBL] [Abstract][Full Text] [Related]
37. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.
Roychowdhury S; May KF; Tzou KS; Lin T; Bhatt D; Freud AG; Guimond M; Ferketich AK; Liu Y; Caligiuri MA
Cancer Res; 2004 Nov; 64(21):8062-7. PubMed ID: 15520217
[TBL] [Abstract][Full Text] [Related]
38. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
39. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
40. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
Santos JM; Havunen R; Siurala M; Cervera-Carrascon V; Tähtinen S; Sorsa S; Anttila M; Karell P; Kanerva A; Hemminki A
Int J Cancer; 2017 Oct; 141(7):1458-1468. PubMed ID: 28614908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
